VIKING THERAPEUT.DL -,005 WKN: A12GD6 ISIN: US92686J1060 Kürzel: VKTX Forum: Aktien Thema: Hauptdiskussion

https://ir.vikingtherapeutics.com/2024-06-04-Viking-Therapeutics-Announces-Positive-52-Week-Histologic-Data-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH

Ich bin sehr gehyped auf halb 4, überlege nochmal aufzustocken was denken die Anderen hier? Andere Biotechs wie Zealand gehen zeitgleich mit Bekanntgabe Vikings Nachrichten runter, auf Stocktwits ist die Stimmung bei Viking ausgezeichnet und der Kurs hatte sein Tief vor kurzem seit dem massiven Anstieg (Februar) bereits erreicht. Übersehe ich was voller Vorfreude? Oder siehts wirklich so gut aus für gleich?

$VKTX NOICE: Viking Therapeutics' VK2809 shows efficacy in Phase 2b NASH study Viking Therapeutics announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis - NASH -. The study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo. Results highlight achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809. On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, vs. 29% for placebo. Across the combined VK2809 treatment groups, 69% achieved NASH resolution. On the secondary endpoint evaluating improvement in fibrosis with no worsening of NASH, VK2809-treated patients demonstrated improvement in fibrosis ranging from 44% to 57% vs. 34% for placebo. Across the combined VK2809 treatment groups, 51% achieved improvement in fibrosis with no worsening of NASH. On the secondary endpoint evaluating the proportion of patients experiencing both resolution of NASH and improvement in fibrosis, VK2809-treated patients demonstrated improvement ranging from 40% to 50% vs. 20% for placebo. Across the combined VK2809 treatment groups, 44% achieved this endpoint. Study results were consistent under various sensitivity analyses. Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, which was the primary endpoint in VOYAGE. Patients receiving VK2809 continued to demonstrate statistically significant reductions in liver fat content at Week 52. Patients receiving VK2809 demonstrated placebo-adjusted reductions in LDL-C ranging from 20% to 25%, as well as reductions in triglycerides and atherogenic proteins and apolipoprotein C-III, all of which have been correlated with cardiovascular risk. VK2809 demonstrated encouraging safety and tolerability in this study through 52 weeks of treatment, with minimal differences compared with the previously reported results at 12 weeks. 94% of treatment related adverse events among patients receiving VK2809 were reported as mild or moderate.

Mich juckts auch in den Fingern, aber ich stecke mit 215 Anteilen schon sehr tief drin

Ganzer Anstieg verpufft, verstehe ich nicht... naja hm

15:30 gehts richtig ab

Ja hoffentlich🙌🏻

Auf wie viel steigt es, zurück auf die 70€? Massiver Anstieg bereits um 13 Uhr. Heftig

Neue Daten sind raus

Boden erreicht?

Hab heute den dip gekauft. Hat ja schon 3x gehalten und short volume scheint auch hoch zu sein

Geduld, wird schon

55,44€ ist der Tiefpunkt der letzten Woche seit dem Anstieg, solange wir das halten geht es wieder bergauf

Die Aktie ist auch nervig

Ich sehe das nicht so pessimistisch! Kann schnell wieder nach oben ausbrechen!